Institutional Ownership
Intellia Therapeutics Inc
CUSIP 45826J105COMNTLAQ1 2026
13D / 13G Filings
43
Schedule 13D/13G on record
Beneficial Filers
14
Distinct reporting persons
Largest Stake
17.9%
Max % of class reported
Institutional Holders
293
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
43 filings · latest Feb 12, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 12, 2026 | The Goldman Sachs Group, Inc. | 13G/A | 11.0% | 3.16M | SEC |
| 2 | Feb 11, 2026 | Contrarius Investment Management Ltd | 13G/A | 0.6% | 714.5K | SEC |
| 3 | Feb 9, 2026 | State Street Corporation | 13G | 5.5% | 6.42M | SEC |
| 4 | Feb 3, 2026 | Ark Investment Management LLC | 13G/A | 12.3% | 14.21M | SEC |
| 5 | Jan 30, 2026 | The Vanguard Group | 13G/A | 11.2% | 13.01M | SEC |
| 6 | Nov 12, 2025 | Contrarius Investment Management Ltd | 13G | 5.5% | 5.89M | SEC |
| 7 | Nov 12, 2025 | The Goldman Sachs Group, Inc. | 13G | 11.0% | 5.50M | SEC |
| 8 | Nov 4, 2025 | Ark Investment Management LLC | 13G/A | 11.1% | 11.92M | SEC |
| 9 | May 13, 2025 | State Street Corporation | 13G | 4.4% | 4.51M | SEC |
| 10 | Apr 17, 2025 | Blackrock, Inc. | 13G/A | 8.2% | 8.45M | SEC |
33 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Intellia Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Ark Investment Management LLC | 14.51M | $186.01M |
| 2 | Blackrock, Inc. | 12.16M | $155.84M |
| 3 | State Street Corp | 6.92M | $88.75M |
| 4 | D. E. Shaw & Co., Inc. | 5.73M | $73.44M |
| 5 | Two Sigma Investments, LP | 4.71M | $60.33M |
| 6 | Regeneron Pharmaceuticals, Inc. | 3.70M | $47.47M |
| 7 | Geode Capital Management, LLC | 2.85M | $36.56M |
| 8 | Ubs Group AG | 2.69M | $34.48M |
| 9 | Dimensional Fund Advisors LP | 2.32M | $29.71M |
| 10 | Morgan Stanley | 2.08M | $26.68M |